Review Article

Functional roles of non-coding RNAs regulated by thyroid hormones in liver cancer

Po-Shuan Huang a,b, Cheng-Chih Chang c, Chia-Siu Wang c, Kwang-Huei Lin a,b,d,e,*

a Department of Biochemistry, College of Medicine, Chang Gung University, Taoyuan, Taiwan
b Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
c Department of General Surgery, Chang Gung Memorial Hospital at Chia yi, Chia yi, Taiwan
d Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
e Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, Taiwan

A R T I C L E  I N F O

Article history:
Received 8 July 2020
Accepted 24 August 2020
Available online 27 August 2020

Keywords:
Non-coding RNA
Thyroid
Receptors
Hepatocellular carcinoma

A B S T R A C T

Recent reports have shown the important role of the non-coding part of human genome RNA (ncRNA) in cancer formation and progression. Among several kinds of ncRNAs, microRNAs (miRNA) play a pivotal role in cancer biology. Accumulating researches have been focused on the importance of non-coding genes in various diseases. In addition to miRNAs, long non-coding RNAs (lncRNAs) have also been extensively documented. Recently, the study of human liver cancer has gradually shifted to these non-coding RNAs that were originally considered “junk”. Notably, dysregulated ncRNAs maybe influence on cell proliferation, angiogenesis, anti-apoptosis, and metastasis. Thyroid hormones play critical roles in human development and abnormalities in thyroid hormone levels are associated with various diseases, such as liver cancer. Thyroid hormone receptors (TR) act as ligand-activated nuclear transcription factors to affect multiple functions through the gene-level regulation in the cells and several studies have revealed that thyroid hormone associated with ncRNAs expression. TR actions are complex and tissue- and time-specific, aberrant expression of the various TR isoforms have different effects and are associated with different types of tumor or stages of development. In this review, we discuss various aspects of the research on the thyroid hormones modulated ncRNAs to affect the functions of human liver cells.

Thyroid hormones (TH) play critical roles in human growth and development and abnormalities in TH levels are associated with various human diseases, such as cancer. Thyroid hormones in the human body affect multiple functions predominantly through gene-level regulation and act as ligand-activated nuclear transcription factors that interact with
their cognate hormone response elements (TRE) in the promoters of different genes to induce positive or negative regulation. In recent years, accumulating research has focused on the importance of non-coding genes in various diseases. In addition to the originally identified microRNAs (miRNA), the physiological relevance of frequently fragmented long non-coding RNAs (lncRNA) has been extensively documented. miRNAs exert their specific effects via direct interactions with three prime untranslated regions (3'UTR) of various target genes, leading to decreased mRNA expression. The molecular mechanisms of lncRNAs in cells are relatively more complex, with different modes of action in the nucleus and cytoplasm. More and more studies, including therapeutic strategies and biomarkers, have been focused on the non-coding RNAs. For example, compared with coding genes, miRNA has the characteristics to affect different target genes' expression and potentially alter several carcinogenic or tumor suppressor pathways at the same time. Besides, the design and implementation of inhibitors or drugs formulated for nucleic acids are easier than those for proteins. Thus, non-coding RNAs have been considered as the most potential targets in cancer treatment. Further, several studies have revealed that the thyroid hormone acts as a transcription factor in association with non-coding genes. The application of thyroid hormones in cancer has long been recognized. Therefore, to understand the relationship between thyroid hormone and non-coding RNAs is an urgent need for clinical application. In the current review, we specifically focus on the miRNAs and lncRNAs affected by thyroid hormones in liver cancer, along with their roles and mechanisms of action in tumor development.

Thyroid hormone in human liver cancer

Hepatocellular carcinoma (HCC)

Hepatocellular carcinoma (HCC) is a common primary malignant tumor of the liver and one of the leading causes of cancer-related death worldwide. The incidence of HCC increases progressively with advancing age in all populations and global cases have continued to rise over the last decade [1]. The burden of liver cancer varies considerably by geographic region and sex due to the distribution of underlying diseases, genetic factors and variable exposure to environmental and behavioral risk factors. Globally, hepatitis B virus (HBV) is the leading cause of liver cancer death, accounting for 33% mortality, followed by alcohol and hepatitis C virus (HCV) infection [2]. While prognosis of patients with HCC is generally poor, the 5-year survival rate is >70% in patients diagnosed at an early stage. However, early diagnosis of HCC is complicated by the coexistence of inflammation and cirrhosis, highlighting the urgent requirement for novel biomarkers of early-stage HCC. Currently, diagnosis of HCC without pathological correlation is achieved by analysis of serum α-fetoprotein (AFP) levels combined with imaging techniques. Advances in genomics and proteomics platforms and biomarker assay techniques over the last decade have resulted in the identification of numerous novel biomarkers and improved diagnosis of HCC. These biomarkers are not only useful for early diagnosis of HCC but also provide insights into the mechanisms driving oncogenesis that could facilitate the development of effective treatment strategies [3]. For instance, Sorafenib is an oral multikinase (receptor tyrosine kinase, RTK) inhibitor that suppresses tumor cell proliferation and angiogenesis and promotes apoptosis. The drug was approved by FDA as a unique target for advanced hepatocellular carcinoma (HCC) in 2007 [4,5] as one of the therapeutic options based on in-depth understanding of the carcinogenic mechanisms underlying liver cancer in recent years. Regrettably, sorafenib prolongs life expectancy by only about 3 months. One of the possible factors is that HCC is a complex disease with multiple signaling pathways involved in its pathogenesis. As a result, the targeted treatment of liver cancer is not effective. Combining the use of a variety of drugs with different mechanisms of action is a new clinical treatment strategy. For example, Sorafenib is combined with a MEK kinase inhibitor. The effect has also been validated to be helpful to patients [6]. The development of different technologies to identify genes with important roles in liver cancer remains a significant focus of scientific and clinical research. To date, several biotechnological methods, including next-generation sequencing and multiple “omics” data analyses including genomics, epigenomics, transcriptomics, proteomics, metabolomics, and metagenomics, have been developed and applied for HCC diagnostic biomarker screening [7].

Thyroid hormone and receptor

The thyroid hormone system starts from the hypothalamus, where thyrotropin-releasing hormone (TRH) is synthesized and released from the periventricular nucleus (PVN). TRH binding to its receptor on the thyrotroph of the anterior pituitary gland stimulates proliferation, synthesis and secretion of thyroid stimulating hormone (TSH). TSH subsequently interacts with the TSH receptor (TSHR) on individual thyroid follicular cells of the thyroid gland to stimulate synthesis and release of the two major thyroid hormone forms, tetraiodothyronine (T₄) and 3,3',5-tri-iodo-ß-thyronine (T₃). T₃ is the active form of thyroid hormone and T₄ the prohormone activated by deiodinases at the cellular and circulatory levels [8]. The actions of T₃ are mediated by nuclear thyroid hormone receptors (TR) located on human chromosomes 17 and 3, which primarily serve as T₃-inducible transcription factors. Two major isoforms of TRs exist, specifically, THRA (TRα) and THRβ (TRβ). Different TRs are composed of similar domains, including an amino-terminal A/B domain to recruit regulatory proteins, a central DNA-binding domain (DBD) or C region displaying high affinity for DNA sequences of TREs, a linker D region necessary for nuclear translocation of the receptor, and a carboxy-terminal ligand-binding domain (LBD) that interacts with thyroid hormones [9]. Expression of TR isoforms is tissue-dependent. TRα is predominantly expressed in bone and heart and TRβ in liver and kidney. Within cells, TR forms a heterodimer with the retinoid X receptor (RXR) that interacts with thyroid hormone response elements (TRE) in regulatory regions of target genes [10].
Role of thyroid hormone and receptor in human liver cancer

Thyroid hormone plays a critical regulatory role in cellular homeostasis and its imbalance in the body is significantly associated with multiple chronic diseases, including obesity, diabetes, cardiovascular, and liver disorders [9]. Under physiological conditions, thyroid hormones control tumor cell development, differentiation, metabolism, and growth pathways. Evidence of TR involvement in human carcinogenesis is based on the discovery of TR mutations in hepatocellular carcinoma, renal clear cell carcinoma, breast cancer, pituitary tumor, and thyroid cancer. Loss of normal expression of THRB located on chromosome 3p due to truncation or deletion has been additionally reported in several malignancies including lung, melanoma, breast, head-and-neck, renal cell, uterine cervical, ovarian, and testicular tumors [11]. In liver, the effects of thyroid hormones appear to be particularly important. The liver has regenerative capacity but is subject to molecular pathologies that may lead to cancer, such as fibrosis, cirrhosis, and non-alcoholic fatty liver disease. In addition, cancer cells undergo reprogramming of their metabolism that results in drastic changes, such as aerobic glycolysis in lieu of oxidative phosphorylation [12]. Hypothyroidism is associated with poorer overall and recurrence-free survival of HCC patients receiving liver transplantation [13]. T3 or its analogs, in addition to reducing the size of the tumor, are known to directly inhibit cell proliferation and migration, induce apoptosis, and reduce tumor growth to different extents by directly targeting the open reading frame (ORF) of target genes [20,27]. In addition to the miR-449 mentioned above, miR-449b, and miR-449c are slightly different in HCC. They have been reported to be overexpressed in many types of cancers, including liver cancer. A mouse model demonstrated that down-regulation of miR-196a inhibited human liver cancer cell migration and invasion in vivo through direct targeting Forkhead box protein O1 (FOXO1) and could benefit the clinical therapy of HCC in the future [25]. MiR-122 and miR-22 are known to be related to the occurrence and progression of HBV related HCC. MiR-122 and miR-22 were downregulated in HBV related HCC patients and were related to tumor size, lymph node metastasis, TNM stage, pathological type, differentiation grade, liver cirrhosis, AFP and HBV DNA in clinical [23].

Non-coding RNAs are a kind of non-coding RNAs [26]. Dysregulated IncRNAs are gradually considered to be closely related to the growth, metastasis, and deterioration of liver cancer [20]. LncRNA Highly Up-regulated in Liver Cancer (HULC) is highly upregulated in HCC and negatively associated with the expression of Phosphatase and Tensin Homolog (PTEN) and miR15a. Further, HULC is related to highly specific upregulation characterized in HCC tissues and associated with intrahepatic metastases, TNM stage, and HCC recurrence [20,27]. In addition to the miR-449 mentioned above, HOXD cluster antisense RNA 1 (HOXD-AS1) also interacts

Thyroid hormone regulates non-coding RNAs in human liver cancer

Non-coding RNAs

Traditionally, the central dogma of molecular biology explaining the destiny of genes is stated as “DNA makes RNA and RNA makes protein”, which subsequently performs the physiological function of its encoded gene. Over the years, the focus of research has gradually shifted to other non-coding RNAs that were originally considered “junk” [15]. These nucleic acids that do not encode proteins not only store and transmit genetic information but also perform vital intracellular functions as regulators of gene expression. Non-coding RNAs are defined by inability to code for peptide chains long enough to constitute proteins (amino acids encoded within the open reading frame (ORF) are <100) and classified based on length of the nucleic acid chain [16]. Typically, microRNAs (miRNA), long non-coding RNAs (lncRNA) and circular RNAs (circRNA) play crucial roles in regulating vital biological processes, especially in malignant diseases [17]. Among these molecules, miRNAs and IncRNAs have been a considerable focus of tumor-related research in recent years. miRNAs are non-coding RNAs about 21–23 nucleotides in size. Compared with other non-coding RNAs with longer fragment sizes, miRNAs perform simple functions and were discovered at an early stage of research. These RNA molecules undergo a series of biogenesis steps that convert primary miRNA transscripts into mature miRNAs, which are subsequently loaded into the RNA-induced silencing complex (RISC) targeting the 3’-untranslated regions (3’ UTR) of target genes, eventually leading to translational repression or target mRNA degradation [18]. In contrast, long non-coding RNAs (>200 nucleotides transcribed by RNA polymerase II) contain introns and present a 7-methylguanosine cap at the 5’ end and a poly(A) chain at the 3’ end, similar to mRNAs.

Compared with miRNA, the mechanisms of action of lncRNAs are complex. LncRNAs can interact with protein, DNA or RNA (RNA-protein, RNA-DNA or RNA–RNA) to perform their functions and are distributed in both nucleus and cytoplasm. In the nucleus, lncRNAs affect downstream gene transcription via multiple roles (enhancer, guide, and decoy or chromatin architect). In the cytoplasm, lncRNAs serve as miRNA/protein sponges or micropeptide templates to affect miRNA translation and stability. Indicating lncRNAs participate many process (epigenetic modification, transcriptional regulation and post-transcriptional regulation) in the cells [19,20].

Non-coding RNAs in liver cancer

Non-coding RNAs have been reported to participate in cancer hallmarks, including uncontrolled cell growth, invasion and metastasis, angiogenesis, resistance to cell death, and evasion of immune destruction [21,22]. MicroRNAs participate in cell proliferation, apoptosis, and transformation, as they can regulate gene expression and intracellular signal transduction for various physiological processes [23]. The tumor-suppressive effects that binding specificities, target genes, and regulated pathways of the miRNA-449 family (miR-449a, miR-449b, and miR-449c) are slightly different in HCC. They inhibited cell proliferation and migration, induced apoptosis, and reduced tumor growth to different extents by directly targeting to SKY-Box Transcription Factor 4 (SOX4), which codes for a transcription factor involved in epithelial–mesenchymal transition (EMT) and HCC metastasis, and thereby inhibited TGF-β mediated cell migration [24]. MiRNA-196a has been reported to be overexpressed in many types of cancers, including HCC. A mouse model demonstrated that down-regulation of miR-196a inhibited human liver cancer cell migration and invasion in vivo through direct targeting Forkhead box protein O1 (FOXO1) and could benefit the clinical therapy of HCC in the future [25]. MiR-122 and miR-22 are known to be related to the occurrence and progression of HBV related HCC. MiR-122 and miR-22 were downregulated in HBV related HCC patients and were related to tumor size, lymph node metastasis, TNM stage, pathological type, differentiation grade, liver cirrhosis, AFP and HBV DNA in clinical [23].

lncRNAs are a kind of non-coding RNAs [26]. Dysregulated IncRNAs are gradually considered to be closely related to the growth, metastasis, and deterioration of liver cancer [20]. LncRNA Highly Up-regulated in Liver Cancer (HULC) is highly upregulated in HCC and negatively associated with the expression of Phosphatase and Tensin Homolog (PTEN) and miR15a. Further, HULC is related to highly specific upregulation characterized in HCC tissues and associated with intrahepatic metastases, TNM stage, and HCC recurrence [20,27]. In addition to the miR-449 mentioned above, HOXD cluster antisense RNA 1 (HOXD-AS1) also interacts
with SOX4. HOXD-AS1 is significantly upregulated in HCC tissues and associated with poor prognosis and high tumor node metastasis stage of HCC patients. HOXD-AS1 competitively binds to miR-130a-3p that prevented SOX4 from miRNA mediated degradation, thus activates the expression of the Enhancer of zeste homolog 2 (EZH2), Matrix Metalloproteinase-2 (MMP-2), and facilitated HCC metastasis [28]. LncRNAs play emerging EMT regulators to differentiate the tumor type (1–3) of EMT, such as Tripartite Motif Containing (TRIM) 71 interacting long non-coding RNA (Triscr)1 that can promote embryonic stem cell self-renewal and suppress ERK target genes through inhibiting TRIM71. Besides, lncRNAs have been found to target EMT-related genes and signaling pathways to increase epithelial plasticity [29]. Moreover, some evidence indicates that IncRNAs are aberrantly expressed in diverse cancer stem cell (CSCs) and regulate CSC properties at different molecular levels. As an example, Differentiation Antagonizing Non-protein Coding RNA (DANCR) can interact with CTNNB1 mRNA and significantly promotes stemness features in HCC [30].

**Non-coding RNAs as biomarker/therapeutic targets for liver cancer**

Serum Alpha-fetoprotein (AFP) is the most used biomarkers for HCC. But, AFP lacks the specificity for use as the standard diagnostic tool for HCC in clinical. Also other biomarkers, such as Desgamma Carboxyprothrombin (DCP) and fucosylated AFP, have been investigated for their clinical usefulness as well but showed equally low accuracy as AFP. Thus, non-coding RNA based assays could be considered as an alternative diagnostic tool for HCC, since most protein-based assays lack the desired accuracy [31]. Many reports suggest that non-coding RNAs alone or in combinations act as candidate biomarkers for HCC diagnosis. The IncRNA Urothelial Carcinoma Associated-1 (UCA1) is an example of IncRNA based HCC diagnostic biomarker. And the simultaneous detection of JUN mRNA was more accurate than the single detection of UCA1 (the sensitivity and specificity were 97.1% and 80%) [32]. Similarly, several miRNAs show their value in clinical diagnosis. For example, miR-26a was identified as a promising biomarker for the diagnosis of early HCC. Even further, the expression levels of miR-221 and miR-101-1 could be used as non-invasive biomarkers for the diagnosis of early HCC from HCV patients [33]. In the choice of biomarker, in addition to the specificity and accuracy of the test, the method of obtaining the specimen is also a very important consideration. Therefore, non-invasive sample acquisition has become the most common consideration. Among them, in the serum of patients, detecting non-coding RNAs in exosomes secreted by cells is a way to obtain higher quality targets to be tested, and it has attracted attention in clinical development [35]. Like circulating exosomal miR-21 and IncRNA Activated By TGF-β (ATB) were related to the TNM stage and other prognostic factors, including the T stage and portal vein thrombosis that can novel prognostic markers and therapeutic targets for HCC [35]. These values underline the utility of RNA based detection methods for early HCC diagnostic.

The application of non-coding RNAs in the HCC therapeutic strategy has great potential. Based on the action characteristics of IncRNA, its function similar to the miRNA plays the role of sponge. Therefore, IncRNAs with different tumor suppressor roles can be designed to inhibit oncogenic miRNAs with the abnormal performance for treatment [36]. Further, IncRNA targeting approaches hold some advantages than protein targeting methods in terms of base pairing principle is much more straightforward than designing a specific protein-binding inhibitor, such as antisense oligonucleotides (ASOs) and RNA interference (RNAi) [37]. For example, linc00210 is highly expressed along with liver tumorigenesis and linc00210 drives the self-renewal and propagation of liver tumor-initiating cells (TiCs) through activating Wnt/β-catenin signaling. Also, ASO-mediated linc00210 silence has been shown to repress the self-renewal and invasion of HCC cells [38]. Besides, knockdown of oncogenic IncRNA cancer susceptibility 9 (CASC9) by RNAi also significantly reduced the tumor formation in an HCC mouse model [39]. Nucleic acid inhibitors can inhibit endogenous miRNAs or piRNAs that exhibit tumor-promoting functions in cancer. Thus, miR-122 inhibitor has been tested in phase 2a clinical trials for treating patients with HCV infection [40].

**Thyroid hormone regulates microRNA expression in liver cancer**

Recent studies have highlighted that thyroid hormone as a transcription factor is closely associated with various non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). In liver cancer, thyroid hormone affects tumor progression through effects on multiple non-coding genes. Our group has extensively investigated miRNAs and lncRNAs with potential clinical value in diagnosis and treatment of liver cancer. As a result, several miRNAs and IncRNAs clearly affected by thyroid hormones and receptors have been identified [38].

MiR-214 is reported to act as either a tumor suppressor or oncogene in various malignancies [42]. The miRNA has been characterized as a tumor suppressor in HCC. Interactions of miR-214 with different target genes exert a range of effects on different cells in HCC. Hepatoma-derived growth factor (HDGF) is a heparin binding protein purified from conditioned medium of HuH-7 hepatoma cells and expressed in a range of tissues, such as liver and lung. Overexpression of HDGF has been reported in multiple cancer types and the HDGF level is correlated with poor prognosis in breast, colorectal, pancreatic, non-small cell lung and gallbladder cancers as well as HCC [43]. Dysregulated miR-214 contributes to the unusual hypervascularity of HCC via direct activation of target genes in the HDGF paracrine pathway of angiogenesis [44,45]. MiR-214 additionally suppresses cell proliferation, migration and metabolism by targeting Flotillin 1 (FLOT1), pyruvate dehydrogenase kinase 2 (PDK2), and plant homeodomain finger protein 6 (PHF6) in hepatocellular carcinoma [42,46]. Previous studies suggest that T3 induces miR-214 expression and suppresses cell proliferation through interactions with the target proto-oncogene, the serine/threonine-protein kinase PIM-1, thus contributing to inhibition of HCC tumor formation [47].

An miRNA cluster is a set of two or more miRNAs transcribed from physically adjacent miRNA genes. In common cognition processes, miRNA clusters are located in similar
chromosomes under the same circumstances and therefore often subject to the same regulation mechanisms or play a consistent role [48]. For instance, the miR-106b-25 cluster regulates atherosclerosis by influencing clearance of VLDL and LDL from the plasma and dysregulation of the miR-183 cluster causes defects in differentiation of photoreceptors and other retinal neurons through effects on target gene expression patterns [49,50]. The miR-199a/miR-214 cluster has additionally been identified as two miRNAs with the similar effects in a number of studies. Both miR-199a and miR-214 are significantly downregulated during differentiation and induce expression of a series of genes correlated with differentiation (COX-2, NF-κB p50/p65, and CREB1) [51]. In addition, miR199/miR214 play roles in the differentiation of mammalian skeletal precursor cells into osteoblasts or chondrocytes, function in the development of muscle and heart, and regulate the development and progression of various cancer types [52]. The transcription factor, Twist-1, drives the expression of a 7.9 kb non-coding RNA transcript (from the Dynamin-3 gene intron) encoding the miR-199a/miR-214 cluster [53].

MiR-199 family members are downregulated in HCC tumors and cell lines in association with poor overall survival. MiR-199a overexpression in HCC cell lines has been shown to inhibit cell proliferation, migration and invasion by targeting Rho-associated coiled-coil kinase 1 (ROCK1), Regulators of G-protein signaling (RGS) and X-box binding protein 1 (XBP1) [54–56]. Interestingly, the miR-199a/miR-214 cluster is subject to the same regulation processes, which seems not so complete. In terms of the effects of thyroid hormones on these miRNAs, the results were unexpected. Earlier studies by our group revealed an interesting regulatory mechanism whereby thyroid hormones exert opposite effects on miR-199a and miR-214. Notably, miR-199a is downregulated by T3/21 while miR-214 is upregulated. The differential regulatory effects on miR-199a and miR-214 are attributed to different TREs in the region between the two miRNAs [47]. Analogous to this finding, miR-17-92 clusters [play distinct roles in lymphomas and solid tumors [57].

MiR-130b acts as an oncogene in HCC, showing significantly higher expression in tumor tissues compared to matched normal tumor-adjacent tissues. Clinical analyses disclosed that high expression of miR-130b is significantly correlated with venous infiltration, high Edmondson-Steiner grade and solid tumors [58]. The serum miR-130b level may present an ideal marker for monitoring the advanced tumor-node-metastasis (TNM) stage [59]. The miR-130b gene inhibits protein expression of Notch-Dll1 to MiR-214. Notably, miR-199a is downregulated by T3/21 while miR-214 is upregulated. The differential regulatory effects on miR-199a and miR-214 are attributed to different TREs in the region between the two miRNAs [47]. Analogous to this finding, miR-17-92 clusters [play distinct roles in lymphomas and solid tumors [57].

MiR-130b overexpression in HCC cells is suggested to aid in diagnosis of HCC [60]. Negative regulation of miR-130b by T3/TR has been reported with the identification of a novel pathway crosslink? T3/TR, miR-130b and its target gene, interferon regulatory factor 1 (IRF1), which affects the EMT-related genes, p-mTOR, p-STAT3, and the p-AKT cascade, in turn, regulating motility and invasion of hepaticoma cells [61].

In addition to miR-130b, miR-21 is a potential tumor biomarker of liver cancer, and combined detection of miR-130b and miR-21 in serum is suggested to aid in diagnosis of HCC [62]. Another study confirmed an oncogenic role of miR-21 and its utility as a potential diagnostic biomarker for early diagnosis of HCC [63]. MiR-21 expression in exosomes is positively correlated with that in cells and negatively correlated with expression of its target genes, such as PTEN, PTENp1 and TET1s, to affect HCC cell growth [64]. Serum visfatin is associated with histology and metastasis of HCC. Serum levels of both visfatin and miR-21 were shown to be significantly higher in HCC patients. Visfatin promoted miR-21 expression and migration of HepG2 cells, suggesting that visfatin-induced HCC cell migration is attributable to upregulation of miR-21 [65]. In addition to visfatin, thyroid hormone affects the performance of miR-21 in HCC. MiR-21 is activated by T3 through its binding to a native T3 response element in the primary promoter region. Stimulation of miR-21 by T3 and subsequent suppression of T-cell lymphoma invasion and metastasis 1 (TIAM1) promotes hepatoma cell migration and invasion [66].

Reports on the role of miR-17 in HCC are controversial and the issue of whether this miRNA plays a carcinogenic or tumor suppressor role is yet to be established. Several studies have shown that miR-17 is highly expressed in HCC, especially in patients with higher risk of metastasis, supporting its utility as a novel prognostic marker [67,68]. MiR17 suppresses postoperative metastasis of hepatocellular carcinoma through blocking the HGF/ERBB3-NF-κB positive feedback loop [71]. Global gene expression profiling data from another investigation indicate that miR-17 targets and inhibits MYC to affect cell cycle progression, supporting the potential of anti-miR-17 as a therapeutic strategy for MYC-driven HCC [72]. T3/TR negatively regulates miR-17 expression in HCC. MiR-17 expression was significantly negatively associated with TRα1 and matrix metalloproteinase-3 (MMP-3) in HCC, suggesting that T3/TR, miR-17 and MMP3 activities are interlinked in the regulation of metastasis [73].

MiR-206 plays an important regulatory role in cell growth in multiple cancer types. Reduced expression of miR-206 has been reported in HCC [74,75]. MiR-206 directly targets the 3’ UTRs of cyclin-dependent kinase 9 (CDK9), cMET and protein tyrosine phosphatase 18 (PTP1B) genes for silencing, in turn, inhibiting HCC proliferation and invasion and simultaneously promoting apoptosis [74–76]. Liver cancer stem cells (CSC) are involved in tumor progression, drug resistance and recurrence of HCC. MiR-206 was reduced in patients with chemoresistant and recurrent HCC and shown to suppress HCC cell dedifferentiation and liver CSC expansion by targeting the epidermal growth factor receptor (EGFR) signaling pathway [77]. The action of thyroid hormone on lipid metabolism in liver is associated with a number of genes involved in lipogenesis and
lipid metabolism. Serum miR-206 expression is reduced in patients with hyperthyroidism. In addition, miR-206 is involved in T₃-mediated regulation of lipid metabolism in HCC cells, indicating a role in thyroid hormone-induced disorders of lipid metabolism in liver [78].

Hepatic lipid droplets (LD) are associated with metabolic syndrome, type 2 diabetes, hepatitis C, and both alcoholic and non-alcoholic fatty liver disease. The novel miRNA, miR-181d, has been identified as an inhibitor that decreases LD levels by about 60%. Data from biochemical assays showed that miRNA-181d reduces cellular triglyceride and cholesterol ester levels that may be relevant in hepatic diseases arising from obesity and alcohol abuse [79]. Thyroid hormone regulates the transcription of numerous metabolic genes in the liver through interactions with its nuclear receptors. MiRNA-181d is regulated by thyroid hormone in hepatic cells and functions in negative regulation of key metabolic genes through effects on two novel thyroid hormone-regulated target genes, caudal type homeobox 2 (CDX2) and sterol O-acyltransferase 2 (SOAT2 or ACAT2) [80].

Thyroid hormone regulates long non-coding RNA expression in liver cancer

In addition to miRNAs, several studies have revealed increasingly important roles of lncRNAs that also belong to the non-coding RNA family. The mechanism of action of lncRNAs is relatively complex, compared to that of miRNAs. Emerging evidence suggests a crucial role of lncRNAs in tumor progression of HCC. Various HCC-related lncRNAs have been shown to display aberrant expression patterns and participate in cancerous phenotypes, such as proliferation, evasion of apoptosis, promotion of vessel formation, and metastasis capability [37]. The most typical lncRNA in HCC associated with the thyroid hormone is brain cytoplasmic RNA 1 (BCYRN1/BC200), a 200-nucleotide ncRNA originally identified as a neuron-specific transcript that is abnormally overexpressed in several tumor types, such as colorectal, breast, lung and liver cancer [81–83]. A number of recent studies have focused on the mechanisms by which abnormal expression of BC200 RNA contributes to cancer development. BC200 expression is reported to be significantly higher in HCC tissues and effective as an independent prognostic marker. Moreover, BC200 affects cell proliferation and migration through influencing c-Myc, Bax and Bcl-xL expression [84] and induces cell growth and tumor sphere formation via regulation of cell cycle-related genes and stemness makers (CD133, CD44, Nanog and Sox2). Simultaneously, BC200 protects cyclin E2 mRNA from degradation via direct interactions and promotes Cdk2–cyclin E2 complex formation [85]. Using the Human Disease-Related lncRNA Profiler to identify the lncRNAs regulated by thyroid hormone in HepG2 cells overexpressing thyroid hormone receptor α1 (HepG2-TRα1), BC200 was identified as an lncRNA downregulated by the thyroid hormone. The results support the existence of a novel pathway involving thyroid hormone-mediated regulation of BC200, cyclin E2 and Cdk2, which, in turn, modulates proliferation and tumor sphere formation of hepatoma cells, highlighting the potential of therapeutic strategies targeting BC200 and associated molecules for treatment of HCC [85].

Our group used microarray analysis for profiling of other important lncRNAs in HepG2-TRα1 cells treated with/without T₃ and HCC specimens. These oncogenic lncRNAs were identified through random sampling verification and downregulated by thyroid hormones [Table 1] [86].

taurine up-regulated gene 1 (TUG1) is an lncRNA shown to play an oncogenic role in various cancers. TUG1 is highly expressed in HCC tissues and contributes to proliferation, metastasis and apoptosis via activation of distal-less homeobox 2 (DLX2) in HCC [94]. In view of the finding that TUG1 can be easily detected in patient samples and has clinical significance, this lncRNA may serve as a novel potential biomarker in HCC, as determined with a valid non-invasive technique [95]. The majority of research to date suggests that TUG1 predominantly acts as a miRNA sponge in HCC, exerting effects on miR-216b-5p, miR-142-3p, miR-144 and miR-132. Interactions of TUG1 with multiple miRNAs lead to its participation in various tumor processes in HCC [94,96–98]. Cancer cells can alter their glucose metabolism and activate aerobic glycolysis [98]. TUG1 is reported to induce cell migration, invasion, and glycolysis through suppression of miR-455-3p. Mir-455-3p directly interacts with the 3’UTR of adenosine monophosphate-activated protein kinase subunit beta 2 (AMPKβ2). The TUG1/miR-455-3p/AMPKβ2 axis regulates cell growth, metastasis, and glycolysis through modulation of hexokinase 2 (HK2) in HCC [100]. Hypothyroidism in patients is associated with high risk of HCC and levels of the glycoprotein, alpha-fetoprotein (AFP), are increased in the majority of patients with HCC. Despite the controversy regarding the utility of AFP, it still present a useful diagnostic biomarker. TUG1 is regulated by thyroid hormone to affect AFP. Specifically, thyroid hormone suppresses TUG1 expression, leading

| LncRNA | In HCC (Fold) | T₃/48 h (Fold) | In HCC Ref. |
|--------|--------------|---------------|------------|
| FAM215A | 7.23 | 0.42 | [67] |
| ANKR200A8 | 2.20 | 0.43 | [81] |
| HCC18 | 2.23 | 0.43 | [82] |
| PVT1 | 7.47 | 0.44 | [83] |
| SNHG1 | 4.69 | 0.45 | [84] |
| SNHG3 | 3.2 | 0.46 | [85] |
| UNK | 3.49 | 0.46 | [86] |
| TUG1 | 3.25 | 0.47 | [87] |
| SNHG7 | 3.30 | 0.47 | [88] |
| DDX11-AS1 | 10.20 | 0.47 | [89] |
| DUSP5P | 9.46 | 0.48 | [90] |
| AGSK1 | 2.79 | 0.49 | [91] |
| MFI2-AS1 | 5.07 | 0.49 | [92] |

Microarray analysis of long non-coding RNA (lncRNA) expression in two pairs of HCC specimens. Data are presented as average tumor/adjacent normal (T/N ratio) of the two specimen pairs. The specified lncRNAs were highly expressed (>2-fold) in HCC specimens. HepG2 cell lines overexpressing TRα1 were treated with thyroid hormone (10 nM) and subjected to microarray analysis of lncRNA expression after 48 h. Notably, the above lncRNAs were negatively affected (<0.5-fold) upon thyroid hormone stimulation. The references pertain to studies on the roles of these lncRNAs in liver cancer.
to downregulation of AFP. AFP is positively correlated with TUG1 levels and unfavorable prognosis in patients with non-hepatitis B/non-hepatitis C (NBNC) HCC [86].

While correlations of thyroid hormone with other lncRNAs have only been observed in our preliminary research, their oncogenic roles in HCC are clear-cut. Family with sequence similarity 215 member A (FAM215A) is a tissue-specific IncRNA with different roles in ovarian cancer and HCC. High expression of FAM215A in low-grade ovarian cancer and early-stage disease has been reported, compared to high-grade ovarian cancer and late-stage disease [101]. In HCC, overexpression of FAM215A is positively correlated with tumor size, vascular invasion, and pathology stage [87]. Overexpression of FAM215A accelerates proliferation and metastasis of HCC cells. FAM215A additionally increases doxorubicin (DOX) resistance in HCC in association with enhanced expression of lysosome-associated membrane protein 2 (LAMP2). Furthermore, FAM215A interacts with and stabilizes LAMP2 to increase tumor progression along with decreasing doxorubicin sensitivity [87].

Long non-coding small nuclear RNA host genes (SNHG) are abnormally expressed in multiple cancers, including urologic neoplasms, respiratory tumors, and digestive cancers, and crucial for tumor progression [102]. SNHGs, including SNHG1, SNHG3, SNHG6, SNHG16, and SNHG20, are reported to play variable roles in HCC via multiple regulatory mechanisms, with both promyotory and inhibitory effects on tumorigenesis [90, 103]. SNHG1 is an oncogenic IncRNA highly expressed in different tumor types, including colorectal, liver, lung, prostate and gastric cancer. Expression of SNHG1 is significantly positively associated with advanced tumor stage, tumor size, TNM stage, and decreased overall survival in liver cancer. Furthermore, aberrant expression of SNHG1 contributes to cell proliferation, metastasis, migration and invasion of HCC cancer cells [104]. Mechanistically, SNHG1 is proposed to act as an miRNA sponge (miR-195-5p and miR-21) and enhance tumor cell proliferation and invasion ability through targeting and inhibition of p53 by binding DNA methyltransferase 1 (DNMT1) [105–107]. Another member of the SNHG family, SNHG3, is highly expressed in HCC tissues and positively correlated with tumor size, portal vein tumor thrombus (PVT), and relapse. Additionally, high expression of SNHG3 is correlated with OS, recurrence-free survival (RFS), and disease-free survival (DFS) [108]. Simultaneously, SNHG3 is suggested to promote tumor invasion and sorafenib resistance by affecting MET via the miR-128/CD151/Akt/Pi3K [109] and miR-326/Sma and Mad Related Family 3 (SMAD3)/zinc finger E-box binding homeobox 1 (ZEB1) signaling pathways [90].

DDX11-AS1 expression is markedly higher in HCC tissues and cell lines and associated with poor predicted overall survival [110]. DDX11-AS1 promotes cell proliferation in gastric cancer through inhibiting miR-30-5p and miR-145-5p [111]. Proliferation, cell cycle progression, migration, and invasion of HCC cells are reduced upon DDX11-AS1 silencing. RNA immunoprecipitation (RIP) and chromatin immunoprecipitation (ChIP) findings suggest that DDX11-AS1 reduces expression of large tumor suppressor kinase 2 (LATS2) by interacting with Enhancer of zeste homolog 2 (EZH2) and DNA (cytosine-5)-methyltransferase 1 (DNMT1) in HCC cells [92].

Discussion

The majority of the human genome is not translatable into protein but can be transcribed into RNA. While non-coding RNAs do not encode proteins, aberrations in these molecules contribute to several disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), Huntington’s disease (HD) and various cancer types [112]. These findings are mainly attributable to the development of high-throughput RNA sequencing technology over the years that has facilitated the discovery of thousands of non-coding RNA genes. A simple sub-classification system is generally used, with ncRNAs divided into short (sncRNAs) and long ncRNAs (lncRNAs) based on a size cut-off of >200 bases. The lncRNA group comprises microRNAs (miRNAs) with small fragment sizes of 21–23 bases [113]. Non-coding RNAs have been shown to be involved in liver cancer progression. For instance, miR-296-5p attenuates the epithelial–mesenchymal transition (EMT) program through Neuregulin (1NRG1)/erb-b2 receptor tyrosine kinase 2 (ERBB2)/ERBB3 signaling. Moreover, miR-296-5p exerts an inhibitory effect on the stemness potency of HCC cells via direct targeting of the Brahma-related gene-1 (BRG1)/Sal-like protein 4 (SALL4) axis [114]. MiR-486-3p is downregulated in sorafenib-resistant HCC cell lines and tumor tissue relative to adjacent normal tissue in HCC patients and could induce apoptosis by targeting fibroblast growth factor receptor 4 (FGFR4) and EGFR [115]. Golgin A2 pseudogene 10 (GOLGA2P10) is frequently upregulated in HCC tissues as well as hepatoma cells subjected to endoplasmic reticulum (ER) stress inducers. Higher GOLGA2P10 levels are correlated with shorter recurrence-free survival of HCC patients. GOLGA2P10 enhances Bcl-xL protein levels and BAD phosphorylation, and confers resistance to ER stress-induced apoptosis in tumor cells [116]. Expression of cancer susceptibility candidate 15 (CASC15) is elevated in HCC tissues and positively correlated with tumor size, TNM stage and metastasis. CASC15 activates the Wnt/b-catenin pathway via enhancing expression of SRY-Box Transcription Factor 4 (SOX4), thus promoting tumor progression [117]. When several non-coding RNAs with different sizes, functions and significance have been identified over the years, this review has mainly focused on the miRNAs and lncRNAs involved in liver cancer and their correlations with the thyroid hormone pathway.

A number of molecular mechanisms have been proposed to explain the involvement of the thyroid hormone and effects on non-coding RNAs in liver cancer [Fig. 1], and thyroid hormone-associated non-coding RNAs including their roles and expression patterns in liver cancer [Table 2] are listed. Thyroid hormones, a transcription factor affect the expression of various non-coding RNAs (miRNAs and lncRNAs). This leads to several regulatory pathways in liver cells. Previously, from ours or other reports indicate that the thyroid hormone is involved in various mechanisms underlying the growth and development of liver cells, inevitably resulting in different roles. An earlier study reported hypothyroidism over ten years in female patients with...
hepatocellular carcinoma, indicating a significant association of hypothyroidism with high risk of HCC in females independent of known risk factors [118]. In clinical samples of liver cancer patients, thyroid-stimulating hormone receptor (TSHR) is overexpressed, indicative of a hypothyroid state [119]. At the same time that in terms of therapeutic strategies, thyroid hormones and/or thyromimetics may be useful for treatment of patients with HCC [14]. Thus, thyroid hormone acts as a transcription factor and its role as a tumor suppressor has been confirmed at the genomic level. We also found that thyroid hormone suppresses HCC development through protecting hepatocytes from HBx-induced damage in transgenic

Table 2 Differential effects of thyroid hormone via regulation of multiple non-coding RNAs in liver cancer.

| Gene   | Role       | Target                  | Function           | T3/TR | Ref. |
|--------|------------|-------------------------|--------------------|-------|------|
| miR-214| Suppressor | HDGF                    | Angiogenesis       | Up    | [44] |
|        |            | FLOT1                   | Proliferation      |       | [46] |
|        |            | PDK2                    | Metastasis         |       | [42] |
|        |            | PHF6                    | Metabolism         |       |      |
|        |            | PIM-1                   |                    |       |      |
| miR-17 | Dual role  | MAPK                    | Proliferation      | Down  | [69] |
|        |            | SMAD3                   | Metastasis         |       | [70] |
|        |            | MYC                     |                    |       | [72] |
|        |            | MMP3                    |                    |       | [73] |
| miR-130b| Oncogene   | Notch–Dl1               | Proliferation      | Down  | [60] |
|        |            | AP-1                    | Metastasis         |       |      |
| BC200  | Oncogene   | IRF1                    | Proliferation      | Down  | [61] |
|        |            | c-Myc                   | Sphere formation   |       | [64] |
|        |            | Bax                     |                    |       |      |
|        |            | Bcl-xL                  |                    |       |      |
|        |            | CD133                   |                    |       |      |
|        |            | CD44                    |                    |       |      |
|        |            | Nanog                   |                    |       |      |
|        |            | Sox2                    |                    |       |      |
|        |            | Cyclin E2               |                    |       |      |

(continued on next page)
mice via activation of PTEN-induced kinase 1 (PINK1) [120]. And in a murine model of diethylnitrosamine (DEN)-induced HCC, thyroid hormone suppresses the carcinogenic process via activation of death-associated protein kinase 2 (DAPK2), a serine/threonine protein kinase, which enhances phosphorylation of sequestosome 1 (SQSTM1) to promote selective autophagic clearance of protein aggregates [121]. The onco-gene, Stathmin (STMN1), is downregulated by thyroid hormone in liver. Thyroid hormone-mediated suppression of STMN1 additionally supports its role as an inhibitor of HCC tumor growth and suggests that lack of normal THR function leads to elevated STMN1 expression and promotes malignancy [122]. As discussed, thyroid hormones play a suppressive role by repressing non-coding RNAs such as miR-214, miR-130b, TUG1 and BC200 to protect liver cells from damage and disease.

Taken together, based on the pathological and clinical analyses and data from different animal models, we propose that thyroid hormone acts as a tumor suppressor to repress several non-coding RNAs as well as coding-genes. In view of the finding that thyroid hormone and its receptor inhibit liver cancer progression, thyroid hormone receptor-β agonists, such as GC-1, MB07344 and KB2115, have been developed as treatment strategies that induce a good response in terms of hepatic metabolism and damage in various animal models. Results from a recent phase II trial consistently showed preventive effects on NAFLD accompanied by improved metabolism (decreased serum levels of LDL cholesterol and TG) [123]. Thus, therapeutic strategies involving modulation of thyroid hormone-regulated non-coding RNAs are feasible for treatment or diagnosis of liver diseases.

Funding

This research was funded by grants from Chang Gung Memorial Hospital, Taoyuan, Taiwan (CMRPF6K0031 to C.-C.C., and C.-S.W) and from the Ministry of Science and Technology of the Republic of China (MOST 106-2314-B-182A-130- to C.-S.W). We would like to thank the Taiwan Liver Cancer Network (TLCN) for providing the hepatoma tissue samples and related clinical data (all anonymous).

Conflict of interest

The authors declare no competing financial interests.

References

[1] Chiew Woon L, Joycelyn Jie Xin L, Su Pin C. Nivolumab for the treatment of hepatocellular carcinoma. Expst Opin Biol Ther 2020;20:687–93.
cancer and the correlation with clinical features. Eur Rev Med Pharmacol Sci 2017;21:742–7.

[24] Sandbothe M, Buurman R, Reich N, Greiwe L, Vajen B, Gurlevik E, et al. The microRNA-449 family inhibits TGF-

beta-mediated liver cancer cell migration by targeting SOX4. J Hepatol 2017;66:1012–21.

[25] Yang L, Peng F, Qin J, Zhou H, Wang B. Downregulation of microRNA-196a inhibits human liver cancer cell proliferation and invasion by targeting FOXO1. Oncol Rep 2017;38:2148–54.

[26] Lim LJ, Wong SYS, Huang F, Lim S, Chong SS, Ooi LL, et al. Roles and regulation of long non-coding RNAs in hepatocellular carcinoma. Canc Res 2019;79:5131–9.

[27] Xin X, Wu M, Meng Q, Wang C, Lu Y, Yang Y, et al. Long noncoding RNA HULC accelerates liver cancer by inhibiting PTEN via autophagy cooperation to miR15a. Mol Canc 2018;17:94.

[28] Wang H, Huo X, Yang XR, He J, Cheng L, Wang N, et al. STAT3-mediated upregulation of IncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Canc 2017;16:136.

[29] Cheng JT, Wang L, Wang H, Tang FR, Cai WQ, Sethi G, et al. Insights into biological role of LncRNAs in epithelial-

mesenchymal transition. Cells 2019;8:1178.

[30] Ma Z, Wang YY, Xin HW, Wang L, Arfuso F, Dharmarajan A, et al. The expanding roles of long non-coding RNAs in the regulation of cancer stem cells. Int J Biochem Cell Biol 2019:108–17–20.

[31] Klingenberger M, Matsuda A, Diederichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets. J Hepatol 2017;67:603–18.

[32] El-Tawdi AH, Matboli M, El-Nakeep S, Azazy AE, Abdel-Rahman O. Association of long non-coding RNA and c-JUN expression in hepatocellular carcinoma. Expet Rev Gastroenterol Hepatol 2016;10:869–77.

[33] Jiang Y, He J, Li Y, Guo Y, Tao H. The diagnostic value of MicroRNAs as a biomarker for hepatocellular carcinoma: a meta-analysis. BioMed Res Int 2019:2019:5179048.

[34] Kelemen E, Danis J, Cobios A, Bata-Csorgo Z, Szell M. Exosomal long non-coding RNAs as biomarkers in human diseases. Ejffcc 2019:30:224–36.

[35] Lee YR, Kim G, Tak WY, Jang SY, Kweon YO, Park JG, et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Int J Canc 2019;144:1444–52.

[36] Xu F, Zha G, Wu Y, Cai W, Ao J. Overexpressing lncRNA SNHG16 inhibited HCC proliferation and chemoresistance by functionally sponging hsa-miR-93. OncoTargets Ther 2018;11:8655–63.

[37] Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Canc 2020;19:77.

[38] Fu X, Zhu X, Qin F, Zhang Y, Lin J, Ding Y, et al. Linc00210 drives Wnt/beta-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner. Mol Canc 2018;17:73.

[39] Klingenberger M, Gross M, Goyal A, Polycarpou-Schwarz M, Miersch T, Ernst AS, et al. The long noncoding RNA cancer susceptibility 9 and RNA binding protein heterogeneous nuclear ribonucleoprotein L form a complex and coregulate genes linked to AKT signaling. Hepatology 2018;68:1817–32.

[40] Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685–94.

[41] Dong H, Paquette M, Williams A, Zoeller RT, Wade M, Yauk C. Thyroid hormone may regulate mRNA abundance in liver by acting on microRNAs. PLoS One 2010;5:e12136.
282

[42] Yu Q, Zhou J, Jian Y, Xiu Z, Xiang L, Yang D, et al. MicroRNA-214 suppresses cell proliferation and migration and cell metabolism by targeting PKD2 and PHF6 in hepatocellular carcinoma. Cell Biol Int 2020;44:117–26.

[43] Yang GY, Zhang AQ, Wang J, Li CH, Wang XQ, Pan K, et al. Hepatoma-derived growth factor promotes growth and metastasis of hepatocellular carcinoma cells. Cell Biochem Funct 2016;34:274–85.

[44] Xia TC, Tian YJ, Wen CJ, Yeh TS, Yu MC, Huang GH, et al. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol 2012;57:584–91.

[45] Liu Y, Wang J, Dong L, Xia L, Zhu H, Li Z, et al. Long noncoding RNA HCP5 regulates pancreatic cancer gemcitabine (GEM) resistance by sponging hsa-miR-214-3p to target HDGF. Oncotargets Ther 2019;12:8207–16.

[46] Liu C, Shang Z, Ma Y, Ma J, Song J. HOTAIR/miR-214-3p/FLOT1 axis plays an essential role in the proliferation, migration, and invasion of hepatocellular carcinoma. Int J Clin Exp Pathol 2019;12:50–63.

[47] Huang PS, Lin YH, Chi HC, Chen PY, Huang YH, Yeh CT, et al. Thyroid hormone inhibits growth of hepatoma cells through induction of miR-214. Sci Rep 2017;7:14868.

[48] Cantini L, Bertoli G, Cava C, Dubosi T, Zinovyev A, Caselle M, et al. Identification of microRNA clusters cooperatively acting on epithelial to mesenchymal transition in triple negative breast cancer. Nucleic Acids Res 2019;47:2205–15.

[49] Semo J, Chernin G, Jonas M, Shimoni S, George J. Deletion of the Mir-106b–25 MicroRNA cluster attenuates atherosclerosis in Apolipoprotein E knockout mice. Lipids Health Dis 2019;18:208.

[50] Amini-Farsani Z, Asgharzade S. The impact of miR-183/182/96 gene regulation on the maturation, survival, and function of photoreceptor cells in the retina. J Comp Neurol 2020;528:1616–25.

[51] Mishra R, Benhabib H, Guo W, Lerma Cervantes CB, Mendelson CR. Developmental decline in the MicroRNA 199a (miR-199a)/miR-214 cluster in human fetal lung promotes type II cell differentiation by upregulating key transcription factors. Mol Cell Biol 2018;38:e00037–18.

[52] Desvignes T, Contreras A, Postlethwait JH. Evolution of the mir199-214 cluster and vertebrate skeletal development. RNA Biol 2014;11:281–94.

[53] Lee YB, Bantounas I, Lee DY, Phylactou L, Caldwell MA, Uney JB. Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res 2009;37:123–8.

[54] Lou Z, Gong YQ, Zhou X, Hu GH. Low expression of miR-199a in hepatocellular carcinoma contributes to tumor cell hyper-proliferation by negatively regulating XBP1. Oncol Lett 2018;16:6531–9.

[55] Zhang W, Qian S, Yang G, Zhu L, Zhou B, Wang J, et al. MicroRNA-199a suppresses cell proliferation, migration and invasion by downregulating RGS17 in hepatocellular carcinoma. Gene 2018;659:22–8.

[56] Zhan Y, Zheng N, Teng F, Bao L, Liu F, Zhang M, et al. MicroRNA-199a/b-5p inhibits hepatocellular carcinoma progression by post-transcriptionally suppressing ROCK1. Oncotarget 2017;8:67169–80.

[57] Ji M, Rao E, Ramachandreddy H, Shen Y, Jiang C, Chen J, et al. The miR-17-92 microRNA cluster is regulated by multiple mechanisms in B-cell malignancies. Am J Pathol 2011;179:1645–56.

[58] Xu Q, Cai W, Zhang M, Liu Q, Liu X. The expression and clinicopathological significance of miR-130b in human hepatocellular carcinoma. Xi bao yu fen zai yue xue za zhi – Chinese journal of cellular and molecular immunology 2016;32:387–92.

[59] Hu XY, Li L, Wu HT, Liu Y, Wang BD, Tang Y. Serum miR-130b level, an ideal marker for monitoring the recurrence and prognosis of primary hepatocellular carcinoma after radiofrequency ablation treatment. Pathol Res Pract 2018;214:1655–60.

[60] Ou C, Peng NF, Li H, Peng YC, Li LQ. The potential mechanism of miR-130b on promotion of the invasion and metastasis of hepatocellular carcinoma by inhibiting Notch-Dll1. J Recept Signal Transduct Res 2020;40:157–65.

[61] Lin YH, Wu MH, Liao CJ, Huang YH, Chi HC, Wu SM, et al. Repression of microRNA-130b by thyroid hormone enhances cell motility. J Hepatol 2015;62:1328–40.

[62] Zhang N, Hu Z, Qiang Y, Zhu X. Circulating miR-130b- and miR-21-21b diagnostic markers and therapeutic targets for hepatocellular carcinoma. Mole Gen Genom Med 2019;7:e1012.

[63] Qi J, Yang J, Chen M, Cui L, Wang T, Gao W, et al. MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: a systematic review and meta-analysis. Pak J Med Sci 2019;35:1466–71.

[64] Cao LQ, Yang XW, Chen YB, Zhang DW, Jiang XF, Xue P. Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth. Mol Canc 2019;18:148.

[65] Liang N, Chen Y, Li L, He S, Liu T. Visfatin increases miR-21 to promote migration in HCC. Cell Mol Biol 2018;64:48–52.

[66] Huang YH, Lin YH, Chi HC, Liao CH, Liao CJ, Wu SM, et al. Thyroid hormone regulation of miR-21 enhances migration and invasion of hepatoma. Canc Res 2013;73:2505–17.

[67] Zheng J, Dong P, Gao S, Wang N, Yu F. High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma. Hepato-Gastroenterology 2013;60:549–52.

[68] Chen L, Jiang M, Yuan W, Tang H. miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg 2012;25:156–61.

[69] Yang F, Yin Y, Wang F, Wang Y, Zhang L, Tang Y, et al. miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology 2010;51:1614–23.

[70] Lu Z, Li X, Xu Y, Chen M, Chen W, Chen T, et al. microRNA-17 functions as an oncogene by downregulating Smad3 expression in hepatocellular carcinoma. Cell Death Dis 2019;10:723.

[71] Liu DL, Lu LL, Dong LL, Liu Y, Bian XY, Lin BF, et al. miR-17-5p and miR-20a-5p suppress postoperative metastasis of hepatocellular carcinoma via blocking HGF/ERBB3-NF-kappaB positive feedback loop. Theranostics 2020;10:3668–83.

[72] Dhanaasekaran R, Gabay-Ryan M, Baylot V, Lai I, Mosley A, Huang X, et al. Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). Oncotarget 2018;9:5517–28.

[73] Lin YH, Liao CJ, Huang YH, Wu MH, Chi HC, Wu SM, et al. Thyroid hormone receptor represses miR-17 expression to enhance tumor metastasis in human hepatoma cells. Oncogene 2013;32:4509–18.

[74] Pang C, Huang G, Luo K, Dong Y, He F, Du G, et al. miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9. Canc Med 2017;6:2398–409.

[75] Wang Y, Tai Q, Zhang J, Kang J, Gao F, Zhong F, et al. MicroRNA-206 inhibits hepatocellular carcinoma cell proliferation and migration but promotes apoptosis by modulating cMET expression. Acta Biochim Biophys Sin 2019;51:243–53.

[76] Yang Q, Zhang L, Zhong Y, Lai L, Li X. miR-206 inhibits cell proliferation, invasion, and migration by down-regulating...
LncRNA SNHG1 promotes cell progression in hepatocellular carcinoma by targeting the miR-21-5p/CDK6 axis. Canc Cell 2019;20:24–36.

[77] Liu C, Li J, Wang W, Zhong X, Xu F, Li J. miR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression. Cell Cycle 2020;19:1077–88.

[78] Zheng Y, Zhao C, Zhang N, Kang W, Lu R, Wu H, et al. Serum microRNA miR-206 is decreased in hyperthyroidism and mediates thyroid hormone regulation of lipid metabolism in HepG2 human hepatoblastoma cells. Mol Med Rep 2018;17:5635–41.

[79] Whittaker R, Loy PA, Sisman E, Suyama E, Aza-Blanc P, Gu L, Lu L, Zhou D, Liu Z. Long noncoding RNA BCYRN1 promotes human hepatocellular carcinoma cell proliferation and migration. J Exp Clin Cancer Res 2019;38:76.

[80] Yap CS, Sinha RA, Ota S, Katsuki M, Yen PM. Thyroid hormone negatively regulates CDX2 and SOAT2 mRNA expression via induction of miRNA-181b in hepatic cells. Biochem Biophys Res Commun 2013;440:635–9.

[81] Shin H, Kim Y, Kim M, Lee Y. BC200 RNA: a emerging therapeutic target and diagnostic marker for human cancer. Mol Cell 2018;41:992–9.

[82] Booy EP, Middumek EK, Kou A, Lin F, McKenna SA. The long non-coding RNA BC200 (BCYRN1) is critical for cancer cell survival and proliferation. Mol Canc 2017;16:109.

[83] Gu L, Lu L, Zhou D, Liu Z. Long noncoding RNA BCYRN1 promotes the proliferation of colorectal cancer cells via up-regulating NFRP expression. Cell Physiol Biochem : Int J Exp Cell Physio Biochem Pharm 2018;48:2337–49.

[84] Tan N, Zhu B, Shu H, Tao YF, Wu JR, Fang M, et al. Effect of LncRNA BC200 on proliferation and migration of liver cancer cells in vitro and in vivo. Oncol Rep 2020;43:461–70.

[85] Lin YH, Wu MH, Huang YH, Yeh CT, Chi HC, Tsai CY, et al. Thyroid hormone negatively regulates tumorigenesis through suppression of BC200. Endocr Relat Canc 2018;25:967–79.

[86] Lin YH, Wu MH, Huang YH, Yeh CT, Lin KH. TUG1 is a regulator of AFP and serves as prognostic marker in non-hepatitis B non-hepatitis C hepatocellular carcinoma. Cells 2020;9:262.

[87] Huang PS, Lin YH, Chi HC, Tseng YH, Chen CY, Lin TK, et al. Dysregulated FAM215A stimulates LAMPP2 expression to confer drug-resistant and malignant in human liver cancer. Cells 2020;9:961.

[88] Jiang B, Yang B, Wang Q, Zheng X, Guo Y, Lu W. LncRNA PVT1 promotes hepatitis B virus positive liver cancer progression by disturbing histone methylation on the CMyc promoter. Oncol Rep 2020;43:718–26.

[89] Qu A, Yang Q. LncRNA SNHG1 promotes cell proliferation and metastasis via sponging miR-377-3p in hepatocellular carcinoma. Neoplasma 2020;67:557–66.

[90] Zhao Q, Wu C, Wang J, Li X, Fan Y, Gao S, et al. LncRNA SNHG3 promotes hepatocellular tumorigenesis by targeting miR-326. Tohoku J Exp Med 2019;249:43–56.

[91] Yang X, Sun L, Wang L, Yao B, Mo H, Wang Y. LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4. Biomedicine & Pharmacotherapy = Biomedecine & pharmacothérapie 2019;118:109386.

[92] Li Y, Zhuang W, Huang M, Li X. Long noncoding RNA DDX1-AS1 epigenetically represses LAT52 by interacting with EZH2 and DNM1L in hepatocellular carcinoma. Biochem Biophys Res Commun 2019;514:1051–7.

[93] Wei Y, Wang Z, Zong Y, Deng D, Chen P, Lu J. LncRNA MF12-AS1 promotes HCC progression and metastasis by acting as a competing endogenous RNA of miR-134 to upregulate FOXM1 expression. Biomed Pharmacother 2020;125:109890.

[94] Dai Q, Deng J, Zhou J, Wang Z, Yuan XF, Pan S, et al. Long non-coding RNA TUG1 promotes cell progression in hepatocellular carcinoma via regulating miR-216b-5p/DLX2 axis. Canc Cell Int 2020;20:38.

[95] Refai NS, Louka ML, Halim HY, Montasser I. Long non-coding RNAs (CASC2 and TUG1) in hepatocellular carcinoma: clinical significance. J Gene Med 2019;21:e3112.

[96] He C, Liu Z, Jin L, Zhang F, Peng X, Xiao Y, et al. IncRNA TUG1-mediated Mir-142-3p downregulation contributes to metastasis and the epithelial-to-mesenchymal transition of hepatocellular carcinoma by targeting ZEB1. Cell Physiol Biochem : Int J Exp Cell Phys Biochem Pharmacother 2018;48:1928–41.

[97] Lv J, Kong Y, Gao Z, Liu Y, Zhu P, Yu Z. LncRNA TUG1 interacting with miR-144 contributes to proliferation, migration and tumorigenesis through activating the JAK2/STAT3 pathway in hepatocellular carcinoma. Int J Biochem Cell Biol 2018;101:19–28.

[98] Li J, Zhang Q, Fan X, Mo W, Dai W, Feng J, et al. The long non-coding RNA TUG1 acts as a competing endogenous RNA to regulate the Hedgehog pathway by targeting miR-132 in hepatocellular carcinoma. Oncotarget 2017;8:65992–45.

[99] Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013;4:e532.

[100] Lin YH, Wu MH, Huang YH, Yeh CT, Cheng ML, Chi HC, et al. Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma. Hepatology 2018;67:188–203.

[101] Fu Y, Biglia N, Wang Z, Shen Y, Risch HA, Lu L, et al. Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINCO00472, in epithelial ovarian cancer. Gynecol Oncol 2016;143:642–9.

[102] Yang H, Jiang Z, Wang S, Zhao Y, Song X, Xiao Y, et al. Long non-coding small nuclear RNA host genes in digestive cancers. Canc Med 2019;8:7693–704.

[103] Shuwen H, Xi Y, Quan Q, Yin J, Miao D. Can small nucleolar RNA hsa snoRNA181 act as a therapeutic target for human colorectal cancer. Oncotarget 2017;8:47410–20.

[104] Thien KZ, Tu JC, Raveendran S. Long non-coding SNHG1 in cancer. Clinica chimica acta. Int J Clin Chem 2019;494:38–47.

[105] Li SJ, Wang L, Sun ZX, Sun SJ, Gao J, Ma RL. LncRNA SNHG1 promotes liver cancer development through inhibiting p53 expression via binding to DNM1L. Eur Rev Med Pharmacol Sci 2019;23:2768–76.

[106] Li W, Dong X, He C, Tan G, Li Z, Zhai B, et al. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Canc Res 2019;38:183.

[107] Huang D, Wei Y, Zhu J, Wang F. Long non-coding RNA SNHG1 functions as a competitive endogenous RNA to regulate PDCD4 expression by sponging miR-195-5p in hepatocellular carcinoma. Gene 2019;733:144384.

[108] Shi M, Zhang XY, Yu H, Xiang SH, Xu L, Wei J, et al. DDX11-AS1 promotes EMT and sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Canc Res 2019;38:183.

[109] Huang D, Wei Y, Zhu J, Wang F. Long non-coding RNA SNHG1 functions as a competitive endogenous RNA to regulate PDCD4 expression by sponging miR-195-5p in hepatocellular carcinoma. Gene 2019;733:144384.

[110] Zhang T, Cao C, Wu D, Liu L. SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma. Tumour Biol 2016;37:2379–85.

[111] Zhang PF, Wang F, Wu J, Wu Y, Huang W, Liu D, et al. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma. J Cell Physiol 2019;234:2788–94.

[112] Shi M, Zhang XY, Yu H, Xiang SH, Xu L, Wei J, et al. DDX11-AS1 as potential therapy targets for human hepatocellular carcinoma. Oncotarget 2017;8:44195–202.
[112] Lekka E, Hall J. Noncoding RNAs in disease. FEBS Lett 2018;592:2884–900.
[113] Hombach S, Kretz M. Non-coding RNAs: classification, biology and functioning. Adv Exp Med Biol 2016;937:3–17.
[114] Shi DM, Shi XL, Xing KL, Zhou HX, Lu LL, Wu WZ. miR-296-5p suppresses stem cell potency of hepatocellular carcinoma cells via regulating Brg1/Sall4 axis. Cell Signal 2020;72:109650.
[115] Ji L, Lin Z, Wan Z, Xia S, Jiang S, Cen D, et al. miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. Cell Death Dis 2020;11:250.
[116] Wu MZ, Fu T, Chen JX, Lin YY, Yang JE, Zhuang SM. LncRNA GOLGA2P10 is induced by PERK/ATF4/CHOP signaling and protects tumor cells from ER stress-induced apoptosis by regulating Bcl-2 family members. Cell Death Dis 2020;11:276.
[117] Wang C, Zi H, Wang Y, Li B, Ge Z, Ren X. LncRNA CASC15 promotes tumour progression through SOX4/Wnt/beta-catenin signalling pathway in hepatocellular carcinoma. Artif Cells Nanomed Biotechnol 2020;48:763–9.
[118] Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, et al. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 2009;49:1563–70.
[119] Shih YL, Huang YH, Lin KH, Chu YD, Yeh CT. Identification of functional thyroid stimulating hormone receptor and TSHR gene mutations in hepatocellular carcinoma. Anticancer Res 2018;38:2793–802.
[120] Chi HC, Chen SL, Lin SL, Tsai CY, Chuang WY, Lin YH, et al. Thyroid hormone protects hepatocytes from HBx-induced carcinogenesis by enhancing mitochondrial turnover. Oncogene 2017;36:5274–84.
[121] Chi HC, Chen SL, Tsai CY, Chuang WY, Huang YH, Tsai MM, et al. Thyroid hormone suppresses hepatocarcinogenesis via DAPK2 and SQSTM1-dependent selective autophagy. Autophagy 2016;12:2271–85.
[122] Tseng YH, Huang YH, Lin TK, Wu SM, Chi HC, Tsai CY, et al. Thyroid hormone suppresses expression of stathmin and associated tumor growth in hepatocellular carcinoma. Sci Rep 2016;6:38756.
[123] Chi HC, Tsai CY, Tsai MM, Yeh CT, Lin KH. Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases. J Biomed Sci 2019;26:24.